An analysis of the SENSCIS trial showed that the rate of decline in forced vital capacity (FVC) was reduced in patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD) treated with nintedanib compared with placebo .
The large, randomised, controlled SENSCIS trial included 576 patients with SSc who also suffered from ILD with an HRCT scan that showed fibrosis affecting at least 10% of the lungs. Participants had a relatively short course of SSc with a maximum disease duration of 7 years. Participants were assigned to 52 weeks of placebo or 150 mg nintedanib twice weekly in addition to their usual immunosuppressive therapy, which in most cases was mycophenolate mofetil (MMF).
“SENSCIS met its primary endpoint: a reduction in the annual rate of decline in FVC,” said Dr Kristin Highland (Cleveland Clinic, Ohio, USA). After a year, in patients who took nintedanib, FVC declined by a mean of 52 mL, which was significantly less than the mean 93 mL decline seen among those who were given placebo. This translated into a 44% lower annual rate of lung function decline in patients taking nintedanib compared with placebo . A subgroup analysis of the SENSCIS data presented at this year´s EULAR meeting showed that patients treated with MMF had a similar benefit from the therapy with nintedanib . Treatment results were also independent of SSc subtype, sex, age, and race .
At the ERS meeting, Dr Highland presented a post-hoc analysis according to percentage of FVC loss. “Improvement with regard to change of FVC began early in treatment, with the efficacy curves separating by week 12 and continuing to diverge,” said Dr Highland. Over 52 weeks, the proportion of patients with any decline in FVC was lower in the nintedanib group compared with placebo, highlighting the high efficacy of the treatment.
The most frequent adverse event during therapy with nintedanib was diarrhoea. Prof. Highland pointed out that this can easily be managed; for example, by concomitant therapy with loperamide or by a dose reduction.
Dr Highland concluded that the open-label SENSCIS on continuation will allow for further data collection on safety and will establish whether treatment effects are sustainable longterm.
- Highland K. Abstract RCT1883, ERS 2019, 29 Sept-2 Oct, Madrid, Spain.
- Distler O, et al. N Engl J Med 2019;380(26):2518-28.
- Distler O, et al. Abstract OP0017, EULAR 2019, 12-15 June, Madrid, Spain.
« COPD patients harbouring Pseudomonas Aeruginosa face high risk of hospitalisation Next Article
Smart shirt as a device to measure tidal volumes in real-life setting »
Table of Contents: ERS 2019
Letter from the Editor
Interview with ERS president Prof. Tobias Welte
Interview with Prof. Bart Lambrecht
Holistic View on Asthma
Holistic view on asthma
COPD patients derive clinical benefit from β-blockers
COPD patients harbouring Pseudomonas Aeruginosa face high risk of hospitalisation
One blood eosinophil count is sufficient to guide ICS therapy
Female COPD patients frequently suffer from anxiety and depression
Dual bronchodilation improves ventilation dynamics in COPD patients
Vaping impairs innate immune response of the airway
Alternative nicotine delivery products: no help in smoking cessation
Pregnant women and their offspring: a high-risk group for air pollution
Taxi drivers exposed to highest levels of black carbon pollution
Infectious Respiratory Disease: the Role of Vaccines
Vaccines show multiple positive effects with respect to respiratory health
Pneumococcal vaccines: an effective way to reduce COPD hospitalisations
Interstitial Lung Disease
Antifibrotic therapy slows disease progression in ILD
Reduction of FVC decline in systemic sclerosis-associated ILD
Registry confirms nintedanib efficacy under real-life conditions
Best of the Posters
Fever during immunotherapy for NSCLC associated with shorter PFS
Smart shirt as a device to measure tidal volumes in real-life setting
Exercise with virtual reality beneficial for COPD patients
NSCLC: A new way to evaluate hilar and mediastinal lymph nodes
COPD patients do not benefit from azithromycin therapy longer than a year
Novel Developments in Infectious Disease
Long-term azithromycin decreases exacerbations in primary ciliary dyskinesia
Predicting community-acquired pneumonia outcomes by microRNA testing
Pulmonary Vascular Disease
Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension
Intravenous N-acetylcysteine performs well in hospitalised patients
Interview with Prof. Antti Lauerma